Table 1.
Patient characteristics
| All (n = 75) | Arm ineligible (n = 23) | Arm eligible (n = 52) | P-value | |
|---|---|---|---|---|
| Age – years | ||||
| Median | 67 | 73 | 62 | 0.054 |
| Range | 46–84 | 46–84 | 50–82 | |
| Sex – no (%) | ||||
| Male | 43 (57) | 14 (61) | 29 (56) | 0.68 |
| Female | 32 (43) | 9 (39) | 23 (44) | |
| ECOG performance status score – no (%) | ||||
| 0 | 11 (15) | 0 (0) | 11 (21) | <0.0001 |
| 1 | 44 (58) | 3 (13) | 41 (79) | |
| 2 | 20 (27) | 20 (87) | 0 (0) | |
| Pancreatic tumor location – no (%) | ||||
| Head | 26 (35) | 9 (39) | 17 (33) | 0.59 |
| Body | 49 (65) | 14 (61) | 35 (67) | |
| Extent of disease – no (%) | ||||
| Locally advanced | 16 (21) | 2 (9) | 14 (27) | 0.076 |
| Distant metastases | 59 (79) | 21 (91) | 38 (73) | |
| No of metastatic sites involved – no (%) | ||||
| 1 | 25 (33) | 4 (17) | 21 (40) | 0.0070 |
| ≥2 | 34 (45) | 17 (74) | 17 (32) | |
| Diagnosis – no (%) | ||||
| Histologically | 46 (61) | 13 (57) | 33 (63) | 0.57 |
| Clinically | 29 (39) | 10 (43) | 19 (37) | |
| Chemotherapy – no (%) | ||||
| Gemcitabine | 53 (71) | 20 (87) | 33 (63) | 0.070 |
| Gemcitabine + S-1 | 15 (20) | 1 (4) | 14 (27) | |
| S-1 | 7 (9) | 2 (9) | 5 (10) | |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; S-1, tegafur-gimeracil-oteracil potassium.